Moderna (MRNA) Stock Forecast & Price Target

Moderna is supported by a diversified mRNA platform that spans infectious disease, oncology, cardiovascular disease, and rare genetic disorders, with 25 development candidates in clinical studies as of March 2026. The positive Phase III INTerpath-001 melanoma data, including a 42% improvement in RFS and 38% in DMFS, strengthens confidence that intismeran could become a major franchise and support expansion into additional cancers. Financially, Moderna also has proforma cash of about $8.52 billion, projected 11% revenue growth to $2.15 billion this year, and enough liquidity to support commercialization and pipeline execution toward profitability in 2028.

Moderna is exposed to substantial clinical, regulatory, and commercial risk, and its mRNA products could fail in the clinic or never gain approval, undermining the core value of its pipeline. Even with 25 mRNA development candidates in clinical studies as of March 2026, the company may still fall short of sales forecasts while spending more than budgeted, which would pressure operating leverage and delay meaningful profitability. As a commercial-stage biotech, it also faces a capital-intensive development model and a shifting capital-raising environment, meaning funding may not be readily available to support its broad programs across infectious disease, oncology, cardiovascular disease, and rare genetic diseases.